Dublin, Sept. 15, 2017 (GLOBE NEWSWIRE) -- The "Drug Discovery Outsourcing Global Market - Forecast to 2025" report has been added to Research and Markets' offering.

Over the last two decades, the Pharmaceutical industry has seen a radical change. The unprecedented downsizing of the internal discovery of big pharmaceuticals, patent expiration, shift towards biologics have seen a surge in the externalization and outsourcing activities. As the industry is looking for new sources of discovery and innovation with limited resources, there is a growing preference to move towards externalization and willingness to embrace the concept of outsourcing.

Almost all the major Pharmaceutical companies are considering outsourcing as a core strategy to fill their discovery pipelines. Outsourcing companies that have precise capabilities through greater flexibility are the preferred ones. Nowadays, the big pharma relies more on CRO's for drug discovery capabilities to stock up their pipelines.

The growth is attributed to the increase in biologics R&D spending and lesser approval time, on the other hand factors such as tedious discovery process and high cost associated are restraining the biologics growth.

The pharmaceutical companies should consider several factors before finalizing a CRO partner like therapeutic area expertise, business model, scientific pool, infrastructure, data security, IP policies and last but not least cost-efficiency. Along with CRO's expertise on drug discovery, the most important aspect the pharma companies look for in a CRO is a verified track record of successfully working in the discovery program of relevant therapeutic area.

Key Topics Covered:

1 Introduction

2 Market Analysis
2.1 Research Methodology
2.2 Forecasting Model
2.3 Market Dynamics
2.4 Market Sizing
2.5 Emerging Trends & Strategies

3 Business Overview
3.1 Business Models
3.2 Business Evolution
3.3 Certifications
3.4 DD Indicators
3.5 Pharma R&D Exp & Intensity

4 Competitor Analysis
4.1 Therapeutic Area Matrix
4.2 Global FTE Rates
4.3 Regional Revenues Vs FTE
4.4 Key players (Revenue Per Employee, Customers, Deals & TA Pie Chart, Collaboration Outcomes)

5 Leading Players
5.1 Overview
5.2 Capabilities
5.3 Therapeutic Area
5.4 Business Models
5.5 Collaborations
5.6 Acquisitions

6 Marketing Strategies
6.1 Conferences
6.2 Match Making Websites
6.3 Virtual Pharmaceuticals
6.4 Online RPFS
6.5 Networking Websites
6.6 Clusters
6.7 Other Marketing Strategies

Companies Mentioned

• Advinus
• AMRI Global
• Aurigene
• Bioduro LLC
• Charles River Laboratories (CRL)
• Chempartner
• Evotec
• GVK Biosciences
• Jubilant Biosys
• Pharmaron Inc.
• Shanghai Medicilon
• Sundia Meditech Co. Ltd.
• Syngene
• TCG Lifesciences
• Wuxiapptec

For more information about this report visit https://www.researchandmarkets.com/research/r7jgns/drug_discovery

CONTACT: Research and Markets
         Laura Wood, Senior Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
         U.S. Fax: 646-607-1907
         Fax (outside U.S.): +353-1-481-1716
         Related Topics: Drug Discovery

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.